Medicina Fluminensis, Vol. 58 No. 3, 2022.
Pregledni rad
https://doi.org/10.21860/medflum2022_280998
Causes of thrombocytopenia in COVID-19 patients
Dora Bežovan
orcid.org/0000-0003-0877-3107
; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
Zdravko Mitrović
orcid.org/0000-0002-9896-1234
; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska, Klinička bolnica Dubrava, Klinika za unutarnje bolesti, Zavod za hematologiju, Zagreb, Hrvatska
Sažetak
Thrombocytopenia is frequent in viral infections. Approximately 18% of COVID-19 patients have thrombocytopenia that is usually mild (ranging from 100 to 150 × 10^9/L). It is more common among critically ill whereby it is an independent risk factor for poor outcome and mortality. Both decreased production and increased consumption of platelets may contribute. Decreased platelet production may occur due to a damage to hematopoietic progenitors and capillary network of the lungs. The consumption of platelets is increased due to their hyperactivation and thrombotic microangiopathy. Immune thrombocytopenia (ITP) and drug-induced thrombocytopenia including heparin-induced thrombocytopenia (HIT) can also develop during COVID-19 treatment.
Ključne riječi
COVID-19; SARS-CoV-2; thrombocytopenia
Hrčak ID:
280998
URI
Datum izdavanja:
1.9.2022.
Posjeta: 2.503 *